Status:
ENROLLING_BY_INVITATION
Long-Term Follow-up Study
Lead Sponsor:
Caribou Biosciences, Inc.
Conditions:
Lymphoma, Non-Hodgkin
Relapsed Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access pr...
Detailed Description
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access pr...
Eligibility Criteria
Inclusion
- Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
- Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
- Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.
Exclusion
- None
Key Trial Info
Start Date :
March 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2041
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05332054
Start Date
March 16 2022
End Date
December 1 2041
Last Update
July 11 2025
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35233
2
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
3
Honor Health Research Institute
Scottsdale, Arizona, United States, 85258
4
University of California Irvine
Irvine, California, United States, 92868